Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meerkat phase III study of intravitreal RO7200220 in uveitic macular edema
CTR20232119Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of vamikibart in uveitic macular edema (UME), noninfectious uveitis (NIU), sponsored by Roche. Started Sep 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)noninfectious uveitis (NIU)
Beyond the preview
Go deeper on CTR20232119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232119.